Overview

A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma

Status:
RECRUITING
Trial end date:
2029-05-31
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, Phase Ib/II clinical study to evaluate the safety and efficacy of nimotuzumab combined with adebrelimab and chemotherapy in patients with recurrent and metastatic head and neck squamous cell carcinoma who are ineligible to high-dose cisplatin treatment.
Phase:
PHASE1
Details
Lead Sponsor:
Fudan University